Graft-versus-Host Disease Modulation by Innate T Cells

Allogeneic cell therapies, defined by genetically mismatched transplantation, have the potential to become a cost-effective solution for cell-based cancer immunotherapy. However, this type of therapy is often accompanied by the development of graft-versus-host disease (GvHD), induced by the mismatched major histocompatibility complex (MHC) between healthy donors and recipients, leading to severe complications and death. To address this issue and increase the potential for allogeneic cell therapies in clinical practice, minimizing GvHD is a crucial challenge. Innate T cells, encompassing subsets of T lymphocytes including mucosal-associated invariant T (MAIT) cells, invariant natural killer T (iNKT) cells, and gamma delta T (γδ T) cells, offer a promising solution. These cells express MHC-independent T-cell receptors (TCRs), allowing them to avoid MHC recognition and thus GvHD. This review examines the biology of these three innate T-cell populations, evaluates research on their roles in GvHD modulation and allogeneic stem cell transplantation (allo HSCT), and explores the potential futures for these therapies.

[1]  Lili Yang,et al.  Mucosal-associated invariant T cells for cancer immunotherapy , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Alisha Chitrakar,et al.  Human Vδ2 T Cells and Their Versatility for Immunotherapeutic Approaches , 2022, Cells.

[3]  Yan-Ruide Li,et al.  Target tumor microenvironment by innate T cells , 2022, Frontiers in Immunology.

[4]  Jiaxi Zhou,et al.  Mucosal-associated invariant T cells predict increased acute graft-versus-host-disease incidence in patients receiving allogeneic hematopoietic stem cell transplantation , 2022, Cancer Cell International.

[5]  Mohammad Hossein Razizadeh,et al.  The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia , 2022, Stem Cell Reviews and Reports.

[6]  Z. Dunn,et al.  Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers , 2022, iScience.

[7]  Sunil S. Raikar,et al.  Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. , 2022, Exploration of immunology.

[8]  Yanqi Yu,et al.  Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity , 2022, Cancers.

[9]  Anastasia I. Kousa,et al.  MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT , 2022, Science Translational Medicine.

[10]  K. Loeb,et al.  Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Z. An,et al.  Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models , 2022, Clinical & translational immunology.

[12]  M. Pellegrini,et al.  Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy , 2021, Cell reports. Medicine.

[13]  Yu Wang,et al.  The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation , 2021, Frontiers in Immunology.

[14]  Lili Yang,et al.  Engineering stem cells for cancer immunotherapy. , 2021, Trends in cancer.

[15]  Xiao-hui Zhang,et al.  γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation , 2021, Frontiers in Immunology.

[16]  Yi Zhang,et al.  The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations , 2021, Frontiers in Immunology.

[17]  E. Jiang,et al.  Regulatory T Cells in GVHD Therapy , 2021, Frontiers in Immunology.

[18]  Howard Y. Chang,et al.  Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects. , 2021, Blood.

[19]  A. Anagnostopoulos,et al.  The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD) , 2021, Journal of clinical medicine.

[20]  A. Lehuen,et al.  MAIT cells, guardians of skin and mucosa? , 2021, Mucosal Immunology.

[21]  A. Sher,et al.  Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates , 2021, Mucosal Immunology.

[22]  K. Schulze-Osthoff,et al.  Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells , 2021, Haematologica.

[23]  Howard Y. Chang,et al.  Invariant natural killer T-cell subsets have diverse graft-versus-host-disease – preventing and antitumor effects , 2021 .

[24]  M. Haniffa,et al.  Donor monocyte–derived macrophages promote human acute graft-versus-host disease , 2020, The Journal of clinical investigation.

[25]  K. Curran,et al.  Low Toxicity and Favorable Overall Survival in Relapsed/Refractory B-ALL following CAR T cells and CD34-selected T Cell Depleted Allogeneic Hematopoietic Cell Transplant. , 2020, Bone Marrow Transplantation.

[26]  S. Ghosh,et al.  c-Rel is a myeloid checkpoint for cancer immunotherapy , 2020, Nature Cancer.

[27]  H. Maecker,et al.  High-Parametric Evaluation of Human Invariant Natural Killer T Cells to Delineate Heterogeneity in Allo- and Autoimmunity. , 2020, Blood.

[28]  Yu Wang,et al.  The Low Number of Mucosal-Associated Invariant T Cells in the Graft Was Associated with Occurrence of Gut Graft-Versus-Host Disease , 2019, Blood.

[29]  J. Heath,et al.  Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. , 2019, Cell stem cell.

[30]  J. Reekie,et al.  Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation , 2019, Front. Immunol..

[31]  J. McCluskey,et al.  The biology and functional importance of MAIT cells , 2019, Nature Immunology.

[32]  M. Martelli,et al.  T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease , 2019, Bone Marrow Transplantation.

[33]  F. Baron,et al.  In Vitro Th17-Polarized Human CD4+ T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  G. Snell,et al.  The complex existence of γδ T cells following transplantation: the good, the bad and the simply confusing , 2019, Clinical & translational immunology.

[35]  B. Sheridan,et al.  Tissue Adaptations of Memory and Tissue-Resident Gamma Delta T Cells , 2018, Front. Immunol..

[36]  Joel Babdor,et al.  Human CD4- invariant NKT lymphocytes regulate graft versus host disease , 2018, Oncoimmunology.

[37]  E. Shpall,et al.  Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. , 2018, Cytotherapy.

[38]  Zhenyi Jin,et al.  Regulatory γδ T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation , 2018, Journal of Translational Medicine.

[39]  P. Hugenholtz,et al.  Recipient mucosal-associated invariant T cells control GVHD within the colon , 2018, The Journal of clinical investigation.

[40]  I. Kato,et al.  Influence of post-transplant mucosal-associated invariant T cell recovery on the development of acute graft-versus-host disease in allogeneic bone marrow transplantation , 2018, International Journal of Hematology.

[41]  M. Labopin,et al.  Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT , 2018, Journal of Hematology & Oncology.

[42]  C. Turtle,et al.  Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[43]  C. Niu,et al.  Gamma-delta (γδ) T cells: friend or foe in cancer development? , 2018, Journal of Translational Medicine.

[44]  R. Negrin,et al.  Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation , 2017, Front. Immunol..

[45]  R. Negrin,et al.  Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. , 2017, Blood.

[46]  M. Mohty,et al.  Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease , 2017, Leukemia.

[47]  M. Bonneville,et al.  Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2 , 2017, Proceedings of the National Academy of Sciences.

[48]  Xiuli Wu,et al.  Increase of Regulatory γδ T Cells Reduces the Incidence of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation , 2016 .

[49]  D. Olive,et al.  BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia , 2016, Oncoimmunology.

[50]  O. Penack,et al.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation , 2016, Bone Marrow Transplantation.

[51]  M. Labopin,et al.  Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. , 2016, Blood.

[52]  P. Matangkasombut,et al.  iNKT Cells and Their Potential Lipid Ligands during Viral Infection , 2015, Front. Immunol..

[53]  E. Adams,et al.  The Role of Mucosal Associated Invariant T Cells in Antimicrobial Immunity , 2015, Front. Immunol..

[54]  H. Sengeløv,et al.  The Role of Gamma Delta T Cells in Haematopoietic Stem Cell Transplantation , 2015, Scandinavian journal of immunology.

[55]  R. Luong,et al.  Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality. , 2015, Blood.

[56]  M. Kronenberg,et al.  Activation and Function of iNKT and MAIT Cells. , 2015, Advances in immunology.

[57]  F. Goldman,et al.  Improving the safety of cell therapy products by suicide gene transfer , 2014, Front. Pharmacol..

[58]  R. Luong,et al.  CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. , 2014, Blood.

[59]  C. Paget,et al.  Role of Non-conventional T Lymphocytes in Respiratory Infections: The Case of the Pneumococcus , 2014, PLoS pathogens.

[60]  Wei He,et al.  Vav1-phospholipase C-γ1 (Vav1-PLC-γ1) Pathway Initiated by T Cell Antigen Receptor (TCRγδ) Activation Is Required to Overcome Inhibition by Ubiquitin Ligase Cbl-b during γδT Cell Cytotoxicity* , 2013, The Journal of Biological Chemistry.

[61]  P. Veys,et al.  The current role of T cell depletion in paediatric stem cell transplantation , 2013, British journal of haematology.

[62]  P. Vantourout,et al.  Six-of-the-best: unique contributions of γδ T cells to immunology , 2013, Nature Reviews Immunology.

[63]  P. Brennan,et al.  Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions , 2013, Nature Reviews Immunology.

[64]  D. Kabelitz,et al.  Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic , 2012, Cellular and Molecular Immunology.

[65]  M. Cavazzana‐Calvo,et al.  Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. , 2012, Blood.

[66]  Carrie R Willcox,et al.  Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor , 2012, Nature Immunology.

[67]  D. Marin,et al.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[68]  D. Olive,et al.  Human Vγ9Vδ2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts , 2012, The Journal of Immunology.

[69]  F. Locatelli,et al.  On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. , 2011, Clinical immunology.

[70]  L. Sangalli,et al.  Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4− Subset Dynamics and Correlates with Remission State , 2011, The Journal of Immunology.

[71]  R. Luong,et al.  Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism. , 2011, Blood.

[72]  J. Novak,et al.  Mechanism of regulation of autoimmunity by iNKT cells. , 2011, Cytokine.

[73]  O. Lantz,et al.  Antimicrobial activity of mucosal-associated invariant T cells , 2010, Nature Immunology.

[74]  P. Debré,et al.  Shaping of iNKT cell repertoire after unrelated cord blood transplantation. , 2010, Clinical immunology.

[75]  K. Mills,et al.  Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. , 2009, Immunity.

[76]  Brit B. Turnbull,et al.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.

[77]  James McCluskey,et al.  Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. , 2009, Immunity.

[78]  P. Marrack,et al.  T cell receptor CDR2 beta and CDR3 beta loops collaborate functionally to shape the iNKT cell repertoire. , 2009, Immunity.

[79]  Xiao-jun Huang,et al.  Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation , 2009, Journal of Clinical Immunology.

[80]  Asha B. Pillai,et al.  Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. , 2009, Blood.

[81]  Michelle L. West,et al.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. , 2009, Blood.

[82]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[83]  L. Gapin,et al.  CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. , 2008, Current opinion in immunology.

[84]  R. Storb,et al.  Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. , 2008, Journal of autoimmunity.

[85]  T. George,et al.  Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease1 , 2007, The Journal of Immunology.

[86]  P. Marrack,et al.  Germline-encoded recognition of diverse glycolipids by natural killer T cells , 2007, Nature Immunology.

[87]  Natalie A. Borg,et al.  CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor , 2007, Nature.

[88]  M. Sykes,et al.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.

[89]  G. Ehninger,et al.  The Graft Content of Donor T Cells Expressing γδTCR+ and CD4+foxp3+ Predicts the Risk of Acute Graft versus Host Disease after Transplantation of Allogeneic Peripheral Blood Stem Cells from Unrelated Donors , 2007, Clinical Cancer Research.

[90]  Asha B. Pillai,et al.  Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation1 , 2007, The Journal of Immunology.

[91]  Albert Bendelac,et al.  The biology of NKT cells. , 2007, Annual review of immunology.

[92]  S. Fuggle,et al.  Expression of MHC Class I–Related Chain B (MICB) Molecules on Renal Transplant Biopsies , 2006, Transplantation.

[93]  D. Fowler.  Shared biology of GVHD and GVT effects: potential methods of separation. , 2006, Critical reviews in oncology/hematology.

[94]  D. Bloch,et al.  Protective conditioning for acute graft-versus-host disease. , 2005, The New England journal of medicine.

[95]  Jiang Zhu,et al.  Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[96]  Y. Tanaka,et al.  Recovery of Vα24+ NKT cells after hematopoietic stem cell transplantation , 2004, Bone Marrow Transplantation.

[97]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[98]  S. Strober,et al.  Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[99]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[100]  B. Blazar,et al.  CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. , 1997, Transplantation.